ArticleJournal of medical toxicology : official journal of the American College of Medical Toxicology2014
Novel use of dexmedetomidine for the treatment of anticholinergic toxidrome.
Article in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 22 citations in OpenAlex.
- Treating Diphenhydramine Overdose: A Literature Review of Currently Available Treatment Methods.Toxics · 2024Review
- The Role of Dexmedetomidine in Pediatric Patients Presenting with an Anticholinergic Toxidrome.Case reports in critical care · 2021Article
- QT interval prolongation and rhabdomyolysis associated with diphenhydramine toxicity: a case report.Journal of community hospital internal medicine perspectives · 2020Article
- Dexmedetomidine as an Adjunct to Treat Anticholinergic Toxidrome in Children.Global pediatric health · 2017Article
- Response: physostigmine may not be the only option for treating anticholinergic syndrome.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2015Article
- Physostigmine is the antidote for anticholinergic syndrome.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2015Article
- Dexmedetomidine Infusion to Control Agitation due to Anticholinergic Toxidromes in Adolescents, a Case Series.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe report the case of an adolescent with anticholinergic toxidrome from diphenhydramine overdose, whose symptoms were treated with a novel application of dexmedetomidine. CASE REPORT: A 13-year-old female developed an anticholinergic toxidrome after intentionally ingesting 9.5 mg/kg of diphenhydramine. Despite routine supportive therapies, to include appropriate doses of lorazepam, she continued to have significant agitation, psychosis, and hallucinations. A dexmedetomidine infusion was started to aid in the treatment of her agitation and psychosis with marked improvement of her symptoms. DISCUSSION: Using dexmedetomidine for the treatment of anticholinergic toxidrome has not been previously described in the literature, but there are multiple reports of its use in alcohol withdrawal syndrome. We suggest that adding dexmedetomidine as an adjunctive agent in the therapy of anticholinergic toxidrome may relieve the symptoms of agitation, psychosis, tachycardia, and hypertension, without the attendant risk of respiratory depression associated with high doses of benzodiazepines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.